Method for treating sepsis

A method of treating sepsis wherein treatment of a patient with a pharmaceutically effective amount of a sPLA2 inhibitor compound of formula I or II is initiated within a time interval from first organ failure or onset of rise in sPLA2 activity levels.

A method of treating sepsis wherein treatment of a patient with a pharmaceutically effective amount of a sPLA2 inhibitor compound of formula I or II or a pharmaceutically acceptable salt, solvate or prodrug derivative thereof, is initiated within a time interval from first organ failure or onset of elevated sPLA2 levels.

A method preventing or treating sepsis comprising the steps of:

• c. selecting patient susceptible to sepsis;
• d. monitoring sPLA2 activity levels in patient;
• e. administering effective amount of a compound of formula I or II if sPLA2 activity levels are high or on the rise.

A method treating sepsis comprising the steps of:

• a. selecting a patient, afflicted with sepsis within 18 hours after first organ failure;
• b. initiating administration of effective amount of a compound of formula I or II;
• c. continuing administration of effective amount of a compound of formula I or II for about 1 to 7 days thereafter or until a medically determined stopping point or sPLA2 activity levels normalize.

A method treating sepsis comprising the steps of:

• a. selecting a patient afflicted with sepsis within 12 hours after first organ failure;
• b. initiating administration of effective amount of a compound of formula I or II or a pharmaceutically acceptable salt, solvate or prodrug thereof.

A method treating sepsis comprising the steps of:

• a. selecting a patient afflicted with sepsis within 6 hours after first organ failure;
• b. initiating administration of effective amount of a compound of formula I or II.

Use of a sPLA2 inhibitor compound of formula I or II or a pharmaceutically acceptable salt, solvate or prodrug derivative thereof, for the manufacture of a medicament for the treatment of sepsis wherein administration of the pharmaceutically effective amount of a sPLA2 inhibitor compound of formula I or II or a pharmaceutically acceptable salt, solvate or prodrug derivative thereof, is initiated within a time interval from first organ failure or onset of elevated sPLA2 levels.

Use of a compound of formula (I) or (II) in the manufacture of a medicament for the treatment or prevention of sepsis in a patient afflicted with sepsis or susceptible to sepsis comprising initiating administration of a pharmaceutical formulation comprising a compound of formula I or II within 24 hours after first organ failure or prior to a rise in sPLA2 levels.

Use of a compound of formula (I) or (II) in the manufacture of a medicament for the treatment or prevention of sepsis in a patient afflicted with sepsis or susceptible to sepsis comprising initiating administration of a pharmaceutical formulation comprising a compound of formula I or II in combination with other effective therapy or co-agent for sepsis within 24 hours after first organ failure or prior to a rise in sPLA2 levels.